In vitro antitumor and immunotropic activity of carrageenans from red algae Chondrus armatus and their low‐molecular weight degradation products

Antitumor and immunotropic effects of κ‐, λ‐carrageenan from red marine algae Chondrus armatus and their low‐molecular weight (LMW) degradation products were explored. Effects on human esophageal cancer cell lines KYSE30 and FLO1 viability and ability to induce production of pro‐ and anti‐inflammato...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Journal of biomedical materials research. Part A 2020-02, Vol.108 (2), p.254-266
Hauptverfasser: Cicinskas, Eduardas, Begun, Maria A., Tiasto, Vladlena A., Belousov, Andrei S., Vikhareva, Valeria V., Mikhailova, Valeria A., Kalitnik, Alexandra A.
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Antitumor and immunotropic effects of κ‐, λ‐carrageenan from red marine algae Chondrus armatus and their low‐molecular weight (LMW) degradation products were explored. Effects on human esophageal cancer cell lines KYSE30 and FLO1 viability and ability to induce production of pro‐ and anti‐inflammatory cytokines by human monocytes was assessed. All polysaccharides demonstrated antimetabolic and cytostatic activity towards cancer lines, with high‐molecular weight carrageenans possessing higher antimetabolic and lower cytostatic activity than their LMW degradation products. All carrageenans induced monocytes to produce pro‐inflammatory cytokines IL1β, IL6, IL18, and TNFα. However, secretion of anti‐inflammatory cytokine IL10 was induced only by LMW λ‐carrageenan, which exhibited the highest cytokine production inducing efficacy overall. We demonstrate that LMW carrageenan degradation products not only retain biological activity of their precursors, but also increase their efficacy in type‐dependent manner, allowing for their future development for pharmacological practice.
ISSN:1549-3296
1552-4965
DOI:10.1002/jbm.a.36812